Passa al contenuto
Merck
  • Rieske iron-sulfur protein induces FKBP12.6/RyR2 complex remodeling and subsequent pulmonary hypertension through NF-κB/cyclin D1 pathway.

Rieske iron-sulfur protein induces FKBP12.6/RyR2 complex remodeling and subsequent pulmonary hypertension through NF-κB/cyclin D1 pathway.

Nature communications (2020-07-17)
Lin Mei, Yun-Min Zheng, Tengyao Song, Vishal R Yadav, Leroy C Joseph, Lillian Truong, Sharath Kandhi, Margarida M Barroso, Hiroshi Takeshima, Marc A Judson, Yong-Xiao Wang
ABSTRACT

Ca2+ signaling in pulmonary arterial smooth muscle cells (PASMCs) plays an important role in pulmonary hypertension (PH). However, the underlying specific ion channel mechanisms remain largely unknown. Here, we report ryanodine receptor (RyR) channel activity and Ca2+ release both are increased, and association of RyR2 by FK506 binding protein 12.6 (FKBP12.6) is decreased in PASMCs from mice with chronic hypoxia (CH)-induced PH. Smooth muscle cell (SMC)-specific RyR2 knockout (KO) or Rieske iron-sulfur protein (RISP) knockdown inhibits the altered Ca2+ signaling, increased nuclear factor (NF)-κB/cyclin D1 activation and cell proliferation, and CH-induced PH in mice. FKBP12.6 KO or FK506 treatment enhances CH-induced PH, while S107 (a specific stabilizer of RyR2/FKBP12.6 complex) produces an opposite effect. In conclusion, CH causes RISP-dependent ROS generation and FKBP12.6/RyR2 dissociation, leading to PH. RISP inhibition, RyR2/FKBP12.6 complex stabilization and Ca2+ release blockade may be potentially beneficial for the treatment of PH.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
SU 5416, ≥98% (HPLC)
Sigma-Aldrich
Myxothiazol, from Myxococcus fulvus Mx f85, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human UQCRFS1